895 related articles for article (PubMed ID: 24391509)
1. NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.
Suenaga Y; Islam SM; Alagu J; Kaneko Y; Kato M; Tanaka Y; Kawana H; Hossain S; Matsumoto D; Yamamoto M; Shoji W; Itami M; Shibata T; Nakamura Y; Ohira M; Haraguchi S; Takatori A; Nakagawara A
PLoS Genet; 2014 Jan; 10(1):e1003996. PubMed ID: 24391509
[TBL] [Abstract][Full Text] [Related]
2. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
[TBL] [Abstract][Full Text] [Related]
3. De novo evolved gene product NCYM in the pathogenesis and clinical outcome of human neuroblastomas and other cancers.
Suenaga Y; Nakatani K; Nakagawara A
Jpn J Clin Oncol; 2020 Aug; 50(8):839-846. PubMed ID: 32577751
[TBL] [Abstract][Full Text] [Related]
4. NCYM promotes calpain-mediated Myc-nick production in human MYCN-amplified neuroblastoma cells.
Shoji W; Suenaga Y; Kaneko Y; Islam SM; Alagu J; Yokoi S; Nio M; Nakagawara A
Biochem Biophys Res Commun; 2015 Jun; 461(3):501-6. PubMed ID: 25896758
[TBL] [Abstract][Full Text] [Related]
5. TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastoma.
Suenaga Y; Yamamoto M; Sakuma T; Sasada M; Fukai F; Ohira M; Yamaguchi Y; Yamamoto T; Ando K; Ozaki T; Nakagawara A
Biochem Biophys Res Commun; 2019 Oct; 518(2):311-318. PubMed ID: 31427086
[TBL] [Abstract][Full Text] [Related]
6. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
7. NCYM is upregulated by lncUSMycN and modulates N-Myc expression.
Liu PY; Atmadibrata B; Mondal S; Tee AE; Liu T
Int J Oncol; 2016 Dec; 49(6):2464-2470. PubMed ID: 27748806
[TBL] [Abstract][Full Text] [Related]
8. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
9. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
10. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
11. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
Gupta A; Williams BR; Hanash SM; Rawwas J
Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
13. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
14. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
15. MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells.
Gu L; Zhang H; He J; Li J; Huang M; Zhou M
Oncogene; 2012 Mar; 31(11):1342-53. PubMed ID: 21822304
[TBL] [Abstract][Full Text] [Related]
16. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma.
Chanthery YH; Gustafson WC; Itsara M; Persson A; Hackett CS; Grimmer M; Charron E; Yakovenko S; Kim G; Matthay KK; Weiss WA
Sci Transl Med; 2012 Jan; 4(115):115ra3. PubMed ID: 22218692
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide decreases MYCN expression and synergizes with retinoic acid in a human MYCN-amplified neuroblastoma cell line.
Chevrier L; Meunier AC; Cochaud S; Muller JM; Chadéneau C
Int J Oncol; 2008 Nov; 33(5):1081-9. PubMed ID: 18949372
[TBL] [Abstract][Full Text] [Related]
18. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
[TBL] [Abstract][Full Text] [Related]
19. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
20. High mobility group A1 is a molecular target for MYCN in human neuroblastoma.
Giannini G; Cerignoli F; Mellone M; Massimi I; Ambrosi C; Rinaldi C; Dominici C; Frati L; Screpanti I; Gulino A
Cancer Res; 2005 Sep; 65(18):8308-16. PubMed ID: 16166307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
